Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding study of ASP015K in moderate to severe rheumatoid arthritis
2011-006020-20Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of peficitinib in rheumatoid arthritis (RA) (5 arms), sponsored by Astellas Pharma. Primary endpoint: ACR20 response rate at Week 12. Started Jun 2012; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-006020-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006020-20.